BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33399078)

  • 1. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
    Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
    ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA; Olszewski AJ
    Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
    Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
    Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
    Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
    Orellana-Noia V; Abousaud A
    Curr Treat Options Oncol; 2022 Oct; 23(10):1443-1456. PubMed ID: 36127571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
    Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
    Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and management of secondary central nervous system lymphoma.
    Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
    Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
    Melchardt T; Hufnagl C; Weinstock DM; Kopp N; Neureiter D; Tränkenschuh W; Hackl H; Weiss L; Rinnerthaler G; Hartmann TN; Greil R; Weigert O; Egle A
    Oncotarget; 2016 Aug; 7(32):51494-51502. PubMed ID: 27285986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell.
    Los-de Vries GT; Stathi P; Rutkens R; Hijmering NJ; Luijks JACW; Groenen PJTA; de Jong D; Ylstra B; Roemer MGM
    Cancer Res; 2023 Jun; 83(11):1917-1927. PubMed ID: 36971477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
    J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
    Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Schlick K; Zaborsky N; Steiner M; Greil R; Egle A; Melchardt T
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33561953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.
    Todorovic Balint M; Jelicic J; Mihaljevic B; Kostic J; Stanic B; Balint B; Pejanovic N; Lucic B; Tosic N; Marjanovic I; Stojiljkovic M; Karan-Djurasevic T; Perisic O; Rakocevic G; Popovic M; Raicevic S; Bila J; Antic D; Andjelic B; Pavlovic S
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27164089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
    Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
    Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
    APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.